Effect of simvastatin on burn-induced alterations in tissue specific glucose metabolism: implications for burn associated insulin resistance.
In addition to their primary role in lowering plasma cholesterol, statins have a variety of other actions. We studied the effect of simvastatin treatment on burn injury-induced changes in regional glucose metabolism. Groups of six CD-1 mice (male, approximately 25 g) were subjected to full thickness 30% total body surface area (TBSA) burn injury. The animals were treated with simvastatin at various doses (0.02, 0.2 and 2.0 microg/kg, i.p.) for seven days. The following morning, mice were injected with 18F labeled 2-fluoro-2-deoxy-D-glucose (18FDG) (50 microCi) via the tail vein. Approximately 60 min after tracer injection, the animals were sacrificed and biodistribution was measured. A sub-set of burned mice with and without statin treatment and sham controls was injected with approximately 1.0 mCi of FDG and tracer distribution was evaluated by microPET. In addition, oral glucose tolerance tests (OGTT) were performed in other groups of burned mice with and without statin treatment and sham controls. In the heart and brown adipose tissue (BAT), burn injury produced a highly significant increase in 18FDG accumulation (p<0.01), whereas tracer accumulation in brain was markedly reduced (p<0.01). In the heart and BAT, simvastatin treatment produced dose-dependent reductions in 18FDG accumulation. In contrast, simvastatin did not affect 18FDG accumulation in the brain. There was no effect of simvastatin treatment on 18FDG accumulation in the heart, BAT or brain of sham-treated mice. Less pronounced effects were detected in other tissues that were studied. All animals had normal plasma glucose levels (approximately 90 mg/dl). The OGTTs demonstrated insulin resistance in burn injured mice which was reversed by statin treatment. Our results indicate that simvastatin reverses burn-induced increases in 18FDG accumulation by the heart and BAT in a dose-dependent manner but does not affect burn-induced reductions of 18FDG accumulation by the brain. These findings suggest that statins exert some of their effects by tissue specific modulation of glucose metabolism.
Bonab
Ali A
AA
Department of Nuclear Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Carter
Edward A
EA
Paul
Kasie
K
Kaneki
Masao
M
Yu
Yong-Ming
YM
Tompkins
Ronald G
RG
Fischman
Alan J
AJ
D000273:Adipose Tissue / Q000378:metabolism; D000818:Animals; D000924:Anticholesteremic Agents / Q000378:metabolism*; D001921:Brain / Q000378:metabolism; D002056:Burns / Q000378:metabolism*; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D005947:Glucose / Q000378:metabolism*; D005951:Glucose Tolerance Test; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D051379:Mice; D009206:Myocardium / Q000378:metabolism; D019275:Radiopharmaceuticals / Q000378:metabolism; D051381:Rats; D019821:Simvastatin / Q000378:metabolism*; D014018:Tissue Distribution
D000924:Anticholesteremic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D019821:Simvastatin; D005947:Glucose